A Phase 4 interventional study of Semaglutide and Virtual Weight Management Coaching in Obesity, Chronic Kidney Disease and Chronic Renal Disease, sponsored by Kristin Clemens. Not yet recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Kristin Clemens · Phase 4, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies testing semaglutide in Obesity — 70 open to participants now, 79 under way, 15 of them phase 3. Semaglutide · Obesity.
Among the 145 studies testing semaglutide in Obesity, this one is the 8th largest by planned enrollment, is one of 6 that started in 2027, is one of 40 in phase 4, reaches primary completion later than 68 of the 78 other live ones, and was the 139th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →70 of the 145 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
McMaster University · Sites in Canada
Ages 18–60
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 25 · Phase 3 47 · Phase 4 40
First in 2014; this study’s year is marked. 6 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 880 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 100 across the 145 interventional studies. Of the 60 that completed or were terminated, 35 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 145 have an industry lead sponsor. The 10 most frequent:
Kristin Clemens is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Kristin Clemens has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
22 of the studies testing semaglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07740291Texas Tech UniversityTirzepatide Impact Assessment Study | 2026-11-23 |
| NCT07430059Vivani Medical, IncSafety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | 2026-12 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
| NCT05173714Srinvasan BeddhuSit Less, Interact and Move More (SLIMM) 2 Study | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 145 studies testing semaglutide in Obesity, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obesity has a serious impact on people's health and quality of life. For those with advanced kidney disease (i.e. approaching the need for dialysis), obesity is especially problematic - obesity can not only lead to worsening kidney function and kidney failure, but it can also prevent patients from receiving a lifesaving kidney transplantation due to concerns about operation risks. Unfortunately, there is an urgent need but no rigorously proven treatments to help people with advanced kidney disease lose weight effectively and safely.
The investigative team is a large team of doctors, nurses, dieticians, exercise specialists, social scientists, and patients with a lived experience, have spent three years advancing research to help people with advanced kidney disease achieve a healthier body weight. They have created a special weight loss program that combines individualized coaching on diet and save activity with a medication proven to help people with healthier kidneys lose weight (i.e. Ozempic). This research program is called PIVOT: Patient-centred Intervention with Virtual support for Obesity and kidney Transplant access.
The investigators have started to test PIVOT in a small pilot study and early results show that there is potential to study the program on a much larger scale (i.e. across Canada). With funding from CIHR, the investigators aim to reach more Canadians with advanced kidney disease (including people of lower income, women, and people of different races) with an aim of helping them lose weight safely, feel better, obtain a kidney transplant, and staying healthier over the longer term.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A maximum tolerated dose of semaglutide will be administered once weekly subcutaneously, up to a dose of 2.0 mg. Participants will also receive nutritional and movement advice, as well as virtual coaching once every 4 weeks for 6 months.
Drug: Semaglutide · Behavioral: Virtual Weight Management Coaching
Usual care participants will continue to receive the typical standard of kidney and diabetes care. They will not receive any study medication or coaching.
Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.
Also known as: Wegovy, Ozempic, Generic Semaglutide, Apo-Semaglutide, Semaglutide Injection
Virtual meeting with intervention coach once every 4 weeks for 6 months, where the coach will discuss the goals and progress with participant, nutritional advice, exercise advice, and motivational support.
Also known as: Coaching, Weight Management
Change in Body Weight
Continuous measure of weight in kilograms assessed on calibrated clinic scales (dry weight for those receiving dialysis given fluid shifts)
Time frame: Baseline to 26 weeks +/- 14 days
Quality of Life - Kidney Disease Quality of Life 36-Item Short Form
Change in Kidney Disease Quality of Life (KDQOL-36) score across treatment arms. KDQOL-36 is scored on a 0-100 scale across five domains, with higher scores indicating better health-related quality of life.
Time frame: Baseline to 26 weeks +/- 14 days
Health-Related Quality of Life - European Quality of Life 5 Dimensions, 5 Level (EQ-5D-5L) Questionnaire
Change in health-related quality of life measured using the European Quality of Life 5-Dimension, 5-Level questionnaire across treatment arms. A score of 11111 = no problems in any dimension (best), and a score of 55555 = extreme problems in all dimensions (worst).
Time frame: Baseline to 26 weeks +/- 14 days
Change in Functional Status - Kidney Disease Quality of Life 36-Item Short form (KDQOL-36)
Change in functional status measured with KDQOL-36™ scores across treatment arms. KDQOL-36 is scored on a 0-100 scale across five domains, with higher scores indicating better health-related quality of life.
Time frame: Baseline to 26 weeks +/- 14 days
Change in Functional Status - European Quality of Life five-dimensional, five-level generic measure (EQ-5D-5L) scores across treatment arms.
Measured via EQ-5D-5L (European Quality of Life five-dimensional, five-level generic measure) scores across treatment arms. A score of 11111 = no problems in any dimension (best), and a score of 55555 = extreme problems in all dimensions (worst).
Time frame: Baseline to 26 weeks +/- 14 days
Weight Loss ≥5%
Percentage of participants achieving at least 5% reduction in body weight from baseline.
Time frame: Baseline to 26 weeks +/- 14 days
Weight Loss ≥10%
Percentage of participant achieving at least 10% reduction in body weight from baseline.
Time frame: Baseline to 26 weeks +/- 14 days
Weight Loss ≥15%
Percentage of participants achieving at least 15% reduction in body weight from baseline.
Time frame: 26 weeks +/- 14 days
Weight Loss ≥20%
Percentage of participants achieving at least 20% reduction in body weight from baseline.
Time frame: Baseline to 26 weeks +/- 14 days
Body Mass Index (BMI)
Change in BMI across treatment arms. Measured in kg/m²
Time frame: Baseline to 26 weeks +/- 14 days
Body Surface Area (BSA)
Change in BSA across treatment arms. Measured in m².
Time frame: Baseline to 26 weeks +/- 14 days
Body Mass Index <35 kg/m²
Percentage of participants achieving a BMI below \<35 kg/m², corresponding to the specified weight-based threshold for transplant listing.
Time frame: Week 26 +/- 14 days
Dalhousie Clinical Frailty Scale Rating
Change in Dalhousie Clinical Frailty Scale rating across treatment arms. The scale ranges from 1 (very fit) to 9 (terminally ill).
Time frame: Baseline to 26 weeks +/- 14 days
SARC-F Score
Change in sarcopenia measured by SARC-F score across treatment arms. This questionnaire is scored out of 10, with a score of 4 or higher indicating probable sarcopenia.
Time frame: Baseline to 26 weeks +/- 14 days
FRAIL Scale
Change in frailty measured by the FRAIL Scale across treatment arms. The scale scores five components - fatigue, resistance, ambulation, illnesses, and loss of weight - on a 0-5 scale, with 0 indicating robust, 1-2 pre-frail, and 3 or more indicating frailty.
Time frame: Baseline to 26 weeks +/- 14 days
Acute Kidney Injury (AKI)
Incidence of AKI. AKI defined by KDIGO as creatinine ≥ 1.5x baseline within 7 days in non-dialysis participants
Time frame: Baseline to 26 weeks +/- 14 days
Hypoglycemia
Incidence of hypoglycemia (blood glucose \<4 mmol/L or time below target using continuous glucose monitoring)
Time frame: Baseline to week 26 +/- 14 days
Gastrointestinal Symptoms
Incidence of gastrointestinal symptoms, including nausea, vomiting, constipation
Time frame: Baseline to 26 weeks +/- 14 days
Acute Biliary Disease
Incidence of acute biliary disease.
Time frame: Baseline to 26 weeks +/- 14 days
Acute Pancreatitis
Incidence of acute pancreatitis.
Time frame: Baseline to 26 weeks +/- 14 days
Diabetic Retinopathy Interventions
Incidence of interventions for diabetic retinopathy
Time frame: Baseline to 26 weeks +/- 14 days
Injection-site reactions
Incidence of injection-site reactions in the intervention arm.
Time frame: Baseline to 26 weeks +/- 14 days
Malignant Neoplasms
Incidence of malignant neoplasms.
Time frame: Baseline to 26 weeks +/- 14 days
Coaching Visit Adherence
Percentage of participants completing ≥4 of 6 coaching visits.
Time frame: Baseline to 26 weeks +/- 14 days
Semaglutide Discontinuation
Percentage of participants discontinuing semaglutide in the intervention arm.
Time frame: Baseline to 26 weeks +/- 14 days
Achievement of semaglutide dose ≥1.0 mg/week
Percentage of participants in the intervention group achieving a semaglutide dose of ≥1.0 mg/week.
Time frame: Week 26 +/- 14 days
Achievement of Semaglutide Dose ≥2.0 mg/week
Percentage of participants achieving a semaglutide dose of ≥2.0 mg/week
Time frame: 26 weeks +/- 14 days
Semaglutide Initiation in Usual Care
Percentage of usual care arm participants initiating semaglutide during the study period.
Time frame: Baseline to 26 weeks +/- 14 days
Use of Semaglutide in Usual Care Participants
Percentage of participants using semaglutide in the usual care arm.
Time frame: Baseline to 26 weeks +/- 14 days
Semaglutide Dose ≥1.0 mg/Week in Usual care Arm
Percentage of usual care participants achieving semaglutide dose ≥1.0 mg/week
Time frame: 26 weeks +/- 14 days
Semaglutide Dose ≥2.0 mg/Week in Usual Care Arm
Percentage of usual care participants achieving semaglutide dose ≥2.0 mg/week
Time frame: 26 Weeks +/- 14 days
Body Fat Percentage Measured with Smart Scale
Change in body fat percentage among the subsample of intervention participants using the study smart scale.
Time frame: Baseline to 26 weeks +/- 14 days
Muscle Mass Measured with Smart Scale
Measured in kilograms. Change in muscle mass among the subsample of intervention participants using the study smart scale.
Time frame: Baseline to 26 weeks +/- 14 days
Intervention Costs
The total cost of the intervention incurred by participants during the 26-week follow-up period, in Canadian dollars (CAD)
Time frame: Baseline to 26 weeks
Out-of-pocket costs
Total out-of-pocket costs incurred by participants during the 26-week study period-including costs directly related to the intervention. Measured in Canadian dollars (CAD)
Time frame: Baseline to 26 weeks
Lost Productivity Costs
Costs associated with productivity losses during the 26-week follow-up period, including costs directly related to the participant's health care and intervention. Measured in Canadian dollars (CAD)
Time frame: Baseline to 26 weeks
Health care utilization costs
Total costs associated with health care utilization during the study period, including physician visits, hospitalizations, emergency department visits, medications, allied health services. Measured in Canadian dollars (CAD) using provincial administrative health data.
Time frame: Baseline to 26 weeks
Change in HbA1c
Change in glycated hemoglobin among participants with diabetes across treatment arms.
Time frame: Baseline to 24 Months
Hospitalization for Hyperglycemia
Incidence of hospitalization for hyperglycemia in participants with diabetes across treatment arms
Time frame: Baseline to 24 Months
Hospitalization for hypoglycemia
Incidence of hospitalization for hypoglycemia in participants with diabetes across treatment arms.
Time frame: Baseline to 24 Months
Initiation of Dialysis
Percentage of non-dialysis participants initiating dialysis across treatment arms
Time frame: Baseline to 24 Months
Cardiovascular Composite
Composite of hospitalization for acute myocardial infarction, stroke, amputation, or heart failure across treatment arms.
Time frame: Baseline to 24 Months
Kidney Transplantation
Percentage of participants receiving kidney transplantation across treatment arms.
Time frame: Baseline to 24 months
Healthcare utilization
Health care utilization over 24 months including number of hospital admissions, emergency department, outpatient and primary care visits, specialist visits, rehabilitation, allied health care visits. Measured using provincial administrative health data.
Time frame: 24 months
Health care costs
Health care costs over 24 months, including total health care costs, hospitalization-related costs, emergency department costs, outpatient and physician costs, medication costs. Measured in Canadian dollars (CAD) using provincial administrative health data.
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.
Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 24 months is below that.
Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide
Kristin Clemens